RAPID SCREENING OF CANCER RELATED GENES

发现与癌细胞有关的基因变化， 增加了对检测这些的方法的改进的需要 突变。 能够快速轻松地扫描序列 癌症相关基因有望最终导致早期检测 以及改善对该疾病的诊断和治疗。 方法将 使用光时间质谱法来开发，以有效和成本 有效地分析一组癌症相关基因， 时尚. 分析的终点是确定 发生突变的位置和类型。 本项目数据 将获得至少数百个样本， 将基因型与病理学相关联的谱数据库， 诊断/预后，从而更好地了解癌的发生。 拟定商业应用： 有研究和医疗诊断的商业应用， 这项研究。 对于研究应用，客户将 制药公司谁将支付服务提供快速和 选择相关基因的突变谱的成本效益知识 患者数据包括对各种治疗剂的反应。 医学诊断测试将基于已知的遗传倾向 对特定疾病的反应以及对不同 基于基因突变的疗法 大型“CLIA”认证临床 实验室将提供测试作为一个专门的产品，基因 跟踪提供仪器和专有试剂。

Discoveries of he genetic changes associated with cancer cells have increased the need for improvements in the methods to detect these mutations. The ability to quickly and easily scan the sequence of cancer-associated genes promises to lead ultimately to earlier detection as well as improved diagnosis and treatment of the disease. Methods will be develop using time-of-light mass spectrometry to efficiently and cost effectively analyze a set of cancer-related genes in an automated fashion. The endpoint of analysis is the identification of the exact location and type of mutation that has occurred. In this project data will be acquired for at least hundreds of samples to create of mutational spectra database correlating genotype with pathology and diagnosis/prognosis, leading to a better understanding of carcinogenesis. PROPOSED COMMERCIAL APPLICATION: There are both research and medical diagnostic commercial application of this research. For research applications, the clients will be pharmaceutical companies who will pay for a service providing rapid and cost-effective knowledge of mutational spectra of select genes correlated with patient data including response to various therapeutic agents. Medical diagnostic test will be based on known genetic predispositions to specific diseases and on known responses of patients to different therapies based on genetic mutation. Large "CLIA" certified clinical laboratories would offer the test as a specialized product, with Gene Trace providing instrumentation and proprietary reagents.